Next-Generation Techniques for Discovering Human Monoclonal Antibodies
- Authors: Lushova A.A.1, Biazrova M.G.1, Prilipov A.G.2, Sadykova G.K.2, Kopylov T.A.3, Filatov A.V.1
-
Affiliations:
- Institute of Immunology
- Ivanovsky Institute of Virology, Gamaleya Scientific Research Institute of Epidemiology and Microbiology
- Orekhovich Institute of Biomedical Chemistry
- Issue: Vol 51, No 6 (2017)
- Pages: 782-787
- Section: Current Trends in the Application of Monoclonal Antibodies Special Issue
- URL: https://journal-vniispk.ru/0026-8933/article/view/163285
- DOI: https://doi.org/10.1134/S0026893317060103
- ID: 163285
Cite item
Abstract
Monoclonal antibodies have found wide applications in the treatment of cancer, as well as of autoimmune, infectious, and other diseases. Several dozen new antibodies are currently undergoing different stages of clinical trials, and some of them will soon be added to the list of immunotherapeutic drugs. Most of these antibodies have been generated using hybridoma technology or a phage display. In recent years, new methods of obtaining human monoclonal antibodies have been actively developing. These methods rely on sequencing immunoglobulin genes from B lymphocytes, as well as on the creation of antibody-secreting stable B-cell lines. The term next-generation antibody-discovery platforms has already been established in the literature to refer to these approaches. Our review focuses on describing the results obtained by these methods.
About the authors
A. A. Lushova
Institute of Immunology
Email: avfilat@yandex.ru
Russian Federation, Moscow, 115478
M. G. Biazrova
Institute of Immunology
Email: avfilat@yandex.ru
Russian Federation, Moscow, 115478
A. G. Prilipov
Ivanovsky Institute of Virology, Gamaleya Scientific Research Institute of Epidemiology and Microbiology
Email: avfilat@yandex.ru
Russian Federation, Moscow, 123098
G. K. Sadykova
Ivanovsky Institute of Virology, Gamaleya Scientific Research Institute of Epidemiology and Microbiology
Email: avfilat@yandex.ru
Russian Federation, Moscow, 123098
T. A. Kopylov
Orekhovich Institute of Biomedical Chemistry
Email: avfilat@yandex.ru
Russian Federation, Moscow, 119121
A. V. Filatov
Institute of Immunology
Author for correspondence.
Email: avfilat@yandex.ru
Russian Federation, Moscow, 115478
Supplementary files
